Upgrade to SI Premium - Free Trial

Intellia Therapeutics (NTLA)

11.63 +0.27 (2.38%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA) September 9, 2026 7:29 AM - StreetInsider Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens September 9, 2026 4:26 AM - StreetInsider FDA accepts Intellia's lonvo-z application with priority review status September 8, 2026 8:10 AM - StreetInsider Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens on HAE Opportunity September 8, 2026 4:25 AM - StreetInsider Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens Before ESC Congress August 25, 2026 4:14 AM - StreetInsider Form 4 Intellia Therapeutics, For: Aug 20 Filed by: LEONARD JOHN M August 24, 2026 4:05 PM - SEC Filing Form 144 Intellia Therapeutics, Filed by: LEONARD JOHN M August 20, 2026 4:04 PM - SEC Filing Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 7, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G Intellia Therapeutics, Filed by: STATE STREET CORP August 7, 2026 9:55 AM - SEC Filing Evercore ISI Upgrades Intellia Therapeutics (NTLA) to Outperform August 6, 2026 4:17 PM - StreetInsider Form 10-Q Intellia Therapeutics, For: Jun 30 August 6, 2026 4:08 PM - SEC Filing Intellia Therapeutics (NTLA) PT Lowered to $49 at Jefferies August 6, 2026 12:55 PM - StreetInsider Form 8-K Intellia Therapeutics, For: Aug 06 August 6, 2026 7:45 AM - SEC Filing Intellia Therapeutics (NTLA) Reports In-Line Q2 EPS August 6, 2026 7:24 AM - StreetInsider Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates August 6, 2026 7:00 AM - Globe NewsWire Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates July 30, 2026 8:00 AM - Globe NewsWire Form 4 Intellia Therapeutics, For: Jul 22 Filed by: Dulac Edward J III July 24, 2026 5:26 PM - SEC Filing Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Underperform July 16, 2026 2:21 AM - StreetInsider Form 4 Intellia Therapeutics, For: Jul 01 Filed by: Dube Michael P July 6, 2026 5:02 PM - SEC Filing Form 4 Intellia Therapeutics, For: Jul 02 Filed by: Dulac Edward J III July 6, 2026 5:01 PM - SEC Filing Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 6, 2026 4:05 PM - Globe NewsWire Form 144 Intellia Therapeutics, Filed by: Dulac Edward J III July 2, 2026 4:34 PM - SEC Filing Full Article List